7 results
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications Summary ... Table Insulin ... Sulfonylureas GLP ... comparison #management #endocrinology ... #dm2
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
- Pharmacology ... Summary Mechanisms ... normally inactivates GLP ... Summary #DM2 #diabetes ... #endocrinology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
Normal and Renal Dosing ... Increase Incretins (GLP-I ... #Pharmacology #Management ... #Diabetes #DM2 ... #Endocrinology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
- Pharmacology ... Summary Mechanisms ... Ozempic), or daily tablet ... #Summary #DM2 # ... diabetes #endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
, GLP-1 receptor ... Diabetes #Mellitus #DM2 ... #Medications #pharmacology ... #comparison #table ... #endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
-1 Agonist Dosing ... oral route by using ... drug to remain stable ... semaglutide #Diabetes #Pharmacology ... #Endocrinology
Allopurinol Pharmacology Summary

Xanthine oxidase inhibitor blocking the formation of new uric acid
Initiate 1-2 days prior to
Allopurinol Pharmacology ... Summary Xanthine ... oxidase inhibitor ... chemotherapy Dosing ... : 100 mg/m2/dose